Appropriate treatment & supervision should be available in case of anaphylactic event. Postpone vaccination in individuals suffering from acute severe febrile illness. Do not administer intravascularly or intradermally. No available data on SC administration. Caution in individuals w/ thrombocytopenia or any coagulation disorder following IM administration. Safety & immunogenicity data are not available for immunocompromised individuals. Patients receiving immunosuppressive treatment or those w/ immunodeficiency may have reduced immune response to Arexvy. Need for revaccination w/ a subsequent dose has not been established. Minor influence on ability to drive & use machines. Not recommended during pregnancy & in breast-feeding/lactating women. Safety & efficacy in childn have not been established.
Sign Out
2445675f-e015-4a1a-90fc-b1620092e188.GIF)
